KCNA3 and breast carcinoma: The mitochondriotropic version of this inhibitor (mitoIN-THPP) was seen to decrease the survival of breast cancer cells and kill melanoma cells, whereas IN-THPP was unable to do it, highlighting the importance of potassium channels located in the mitochondrial membrane as privileged pharmacological targets in the therapy of various forms of cancer [216].